



## Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

February 26, 2025 at 7:00 AM EST

WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in March 2025 as follows:

- Leerink's Global Biopharma Conference 2025 to take place from March 10<sup>th</sup> to March 12<sup>th</sup>: fireside chat to take place on Monday, March 10<sup>th</sup> at 4:20-4:50pm EST; management will also be available for 1x1 meetings
- Barclays 27th Annual Global Healthcare Conference to take place from March 11<sup>th</sup> to March 13<sup>th</sup>; management will also be available for 1x1 meetings on March 12<sup>th</sup>

A webcast of the presentation at the Leerink's Global Biopharma Conference 2025 will be available under the "Events and Presentation" page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit [investors.aquestive.com](https://investors.aquestive.com).

### About Aquestive Therapeutics, Inc.

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm<sup>®</sup>, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for the treatment of possible various dermatology conditions, including alopecia areata. For more information, visit [Aquestive.com](https://www.aquestive.com) and follow us on LinkedIn.

### Forward Looking Statement

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement for clinical development and approval by the U.S. Food and Drug Administration of the Company's product candidates, including AQST-109 for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 for the treatment of possible various dermatology conditions, including alopecia areata. These forward-looking statements are based on the Company's current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the "Risk Factors" section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm<sup>®</sup> and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

### Investor Contact:

Brian Korb  
astr partners  
[brian.korb@astrpartners.com](mailto:brian.korb@astrpartners.com)